JP2017538680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538680A5 JP2017538680A5 JP2017525120A JP2017525120A JP2017538680A5 JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5 JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- recurrence
- therapeutic agent
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075532P | 2014-11-05 | 2014-11-05 | |
| US62/075,532 | 2014-11-05 | ||
| PCT/US2015/059297 WO2016073759A1 (en) | 2014-11-05 | 2015-11-05 | Combination immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538680A JP2017538680A (ja) | 2017-12-28 |
| JP2017538680A5 true JP2017538680A5 (https=) | 2018-12-13 |
| JP7305300B2 JP7305300B2 (ja) | 2023-07-10 |
Family
ID=55909820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525120A Active JP7305300B2 (ja) | 2014-11-05 | 2015-11-05 | 併用免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11236139B2 (https=) |
| EP (1) | EP3215182B1 (https=) |
| JP (1) | JP7305300B2 (https=) |
| WO (1) | WO2016073759A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356163B (es) | 2011-12-01 | 2018-05-16 | Chemocentryx Inc | Anilinas sustituidas como antagonistas de ccr(4). |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| TN2019000101A1 (en) | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2017201502A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| WO2017207814A1 (en) | 2016-06-02 | 2017-12-07 | Ultimovacs As | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| US20210030838A1 (en) | 2017-09-21 | 2021-02-04 | University Of Copenhagen | Chemotaxis-potentiating peptides and uses thereof |
| EP3790895A4 (en) * | 2018-05-10 | 2022-05-11 | The Regents of the University of California | CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER |
| CN112601526B (zh) * | 2018-08-29 | 2025-10-03 | 凯莫森特里克斯股份有限公司 | 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗 |
| WO2020198401A1 (en) * | 2019-03-26 | 2020-10-01 | Translational Drug Development, Llc | Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type |
| EP3999092A4 (en) * | 2019-07-17 | 2023-08-09 | The Regents of the University of California | Combination cancer therapy agents and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| DE69019727T2 (de) | 1989-09-21 | 1995-10-19 | Idemitsu Kosan Co | Arylstyrolpolymer und -copolymer und verfahren zu ihrer herstellung. |
| WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US20030175801A1 (en) | 2001-04-18 | 2003-09-18 | Dubinett Steven M. | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20110059137A1 (en) | 2008-03-21 | 2011-03-10 | H. Lee Moffitt Cancer Center And Research Institutute, Inc | Chemokine gene-modified cells for cancer immunotherapy |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| CN104507538B (zh) * | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| MX2018010362A (es) | 2016-02-29 | 2019-03-28 | Found Medicine Inc | Metodos y sistemas para evaluar carga mutacional de tumores. |
| EP4317422A3 (en) * | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP3790895A4 (en) | 2018-05-10 | 2022-05-11 | The Regents of the University of California | CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER |
-
2015
- 2015-11-05 EP EP15856689.3A patent/EP3215182B1/en active Active
- 2015-11-05 US US15/524,740 patent/US11236139B2/en active Active
- 2015-11-05 WO PCT/US2015/059297 patent/WO2016073759A1/en not_active Ceased
- 2015-11-05 JP JP2017525120A patent/JP7305300B2/ja active Active
-
2022
- 2022-01-18 US US17/577,973 patent/US20220162279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538680A5 (https=) | ||
| Kabacaoglu et al. | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options | |
| Hilmi et al. | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? | |
| Van Limbergen et al. | Combining radiotherapy with immunotherapy: the past, the present and the future | |
| Kershaw et al. | Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment | |
| JP2018502120A5 (https=) | ||
| Van der Jeught et al. | Targeting the tumor microenvironment to enhance antitumor immune responses | |
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| IL318946A (en) | Combinations of checkpoint inhibitors and cancer drugs | |
| JP2020505342A5 (https=) | ||
| JP2016527286A5 (https=) | ||
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| JP2012196206A5 (https=) | ||
| Haddad et al. | Using viral vectors to deliver local immunotherapy to glioblastoma | |
| JP2018023397A5 (https=) | ||
| JP2019517508A5 (https=) | ||
| Catani et al. | Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma | |
| Giavedoni et al. | Acne fulminans successfully treated with cyclosporine and isotretinoin | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances | |
| Bolm et al. | Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer | |
| Ji et al. | Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors | |
| Fatemi et al. | Emerging frontiers in colorectal cancer therapy: From targeted molecules to immunomodulatory breakthroughs and cell-based approaches |